Werewolf Therapeutics, Inc., a biotechnology company focused on developing innovative cancer therapies, has released its Form 10-Q report for the second quarter of 2025. The report provides a detailed overview of the company's financial performance and key business developments, highlighting its ongoing efforts in product development and strategic collaborations.\n\nFinancial Highlights\nCollaboration Revenue: $0 million. No revenue was recognized during the three and six months ended June 30, 2025, following the execution of the Transfer Agreement with Jazz in June 2024.\nOperating Loss: $17.5 million for the three months ended June 30, 2025, compared to $19.0 million for the same period in 2024, reflecting a decrease in operating expenses.\nNet Loss: $18.0 million for the three months ended June 30, 2025, compared to $17.2 million for the same period in 2024, primarily due to decreased interest income and increased interest expense.\nNet Loss Per Share, Basic: $0.40 for the three months ended June 30, 2025, consistent with the same period in 2024.\nNet Loss Per Share, Diluted: $0.40 for the three months ended June 30, 2025, compared to $0.43 for the same period in 2024, reflecting the impact of the conversion option derivative under the K2HV Loan Agreement.\n\nBusiness Highlights\nProduct Development: Werewolf Therapeutics is advancing its INDUKINE and INDUCER molecules, with WTX-124 and WTX-330 being the most advanced candidates. WTX-124 is in a Phase 1/1b clinical trial, both as a monotherapy and in combination with Merck's KEYTRUDA, targeting advanced or metastatic solid tumors. WTX-330 has completed Phase 1 and is now in a Phase 1b/2 trial for selected solid tumors.\nPipeline Expansion: The company is expanding its PREDATOR platform to include new preclinical candidates like WTX-712, WTX-518, and WTX-921, targeting various immune-mediated conditions. WTX-712 and WTX-518 have shown promising preclinical data, with presentations at the AACR Annual Meeting.\nCollaboration and Licensing: The collaboration with Jazz Pharmaceuticals on the JZP898 molecule has completed its material performance obligations, with future revenue dependent on achieving development and regulatory milestones.\nClinical Trials and Regulatory Pathways: Werewolf plans to present interim data from ongoing trials in the second half of 2025 and engage with regulatory authorities to discuss potential accelerated approval pathways for WTX-124.\nFuture Outlook: The company anticipates continued substantial research and development expenses as it progresses its clinical trials and preclinical development. Werewolf is also exploring potential collaborations and strategic alliances to support its growth strategy.\n\nSEC Filing: Werewolf Therapeutics, Inc. [ HOWL ] - 10-Q - Aug. 14, 2025

GALECTIN Therapeutics Inc SEC 10-Q Report

Werewolf Therapeutics, Inc. has published its Form 10-Q report for the second quarter of 2025, detailing its financial performance and business developments. The company reported an operating loss of $17.5 million, a net loss of $18.0 million, and no collaboration revenue for the period. It continues to advance its INDUKINE and INDUCER molecules, including WTX-124 in a Phase 1/1b trial and WTX-330 in a Phase 1b/2 trial. The company is expanding its PREDATOR platform with new preclinical candidates and has completed material performance obligations under its collaboration with Jazz Pharmaceuticals. Future plans include presenting interim trial data and exploring strategic alliances.